We have previously demonstrated differential responses to anti–PD-1/anti–PD-L1 of two K-Ras–mutant lung cancer cells, with CMT167 tumors showing a strong inhibition and LLC tumors being resistant to therapy (Li et al, 2017). This evidence concerns the gene KRAS and lung cancer.